Israel - English - Ministry of Health

perrigo israel agencies ltd - estriol - cream - estriol 0.1 % - estriol - estriol - for the treatment of vulvo-vaginal complaints related to estrogen deficiency.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries limited - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

haupt pharma munster gmbh - letrozole - tablets film-coated - 2,5mg

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

american health packaging - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

app pharmaceuticals, llc - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [ see clinical studies ( 14.2, 14.3) ]. letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [ see clinical studies ( 14.4, 14.5) ]. - pregnancy: letrozole can cause fetal harm [ see use in specific populations ( 8.1) ]. pr